TrialCancer medicine2014

A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer.

Edward H Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.